Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer

Kohei Miyata, Fusanori Yotsumoto, Satoshi Fukagawa, Chihiro Kiyoshima, Nam Sung Ouk, Daichi Urushiyama, Tomohiro Ito, Takahiro Katsuda, Masamitsu Kurakazu, Ryota Araki, Ayako Sanui, Daisuke Miyahara, Masaharu Murata, Kyoko Shirota, Hiroshi Yagi, Tadao Takono, Kiyoko Kato, Nobuo Yaegashi, Kohei Akazawa, Masahide KurokiShin'ichiro Yasunaga, Shingo Miyamoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HBEGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.

Original languageEnglish
Pages (from-to)3955-3960
Number of pages6
JournalAnticancer research
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Epidermal Growth Factor
Ovarian Neoplasms
Heparin
Intercellular Signaling Peptides and Proteins
Biomarkers
Serum
Neoplasms
Antineoplastic Agents
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Miyata, K., Yotsumoto, F., Fukagawa, S., Kiyoshima, C., Sung Ouk, N., Urushiyama, D., ... Miyamoto, S. (2017). Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticancer research, 37(7), 3955-3960. https://doi.org/10.21873/anticanres.11779

Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. / Miyata, Kohei; Yotsumoto, Fusanori; Fukagawa, Satoshi; Kiyoshima, Chihiro; Sung Ouk, Nam; Urushiyama, Daichi; Ito, Tomohiro; Katsuda, Takahiro; Kurakazu, Masamitsu; Araki, Ryota; Sanui, Ayako; Miyahara, Daisuke; Murata, Masaharu; Shirota, Kyoko; Yagi, Hiroshi; Takono, Tadao; Kato, Kiyoko; Yaegashi, Nobuo; Akazawa, Kohei; Kuroki, Masahide; Yasunaga, Shin'ichiro; Miyamoto, Shingo.

In: Anticancer research, Vol. 37, No. 7, 07.2017, p. 3955-3960.

Research output: Contribution to journalArticle

Miyata, K, Yotsumoto, F, Fukagawa, S, Kiyoshima, C, Sung Ouk, N, Urushiyama, D, Ito, T, Katsuda, T, Kurakazu, M, Araki, R, Sanui, A, Miyahara, D, Murata, M, Shirota, K, Yagi, H, Takono, T, Kato, K, Yaegashi, N, Akazawa, K, Kuroki, M, Yasunaga, S & Miyamoto, S 2017, 'Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer', Anticancer research, vol. 37, no. 7, pp. 3955-3960. https://doi.org/10.21873/anticanres.11779
Miyata, Kohei ; Yotsumoto, Fusanori ; Fukagawa, Satoshi ; Kiyoshima, Chihiro ; Sung Ouk, Nam ; Urushiyama, Daichi ; Ito, Tomohiro ; Katsuda, Takahiro ; Kurakazu, Masamitsu ; Araki, Ryota ; Sanui, Ayako ; Miyahara, Daisuke ; Murata, Masaharu ; Shirota, Kyoko ; Yagi, Hiroshi ; Takono, Tadao ; Kato, Kiyoko ; Yaegashi, Nobuo ; Akazawa, Kohei ; Kuroki, Masahide ; Yasunaga, Shin'ichiro ; Miyamoto, Shingo. / Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. In: Anticancer research. 2017 ; Vol. 37, No. 7. pp. 3955-3960.
@article{032f254bab194fd294088519efd2f02d,
title = "Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer",
abstract = "Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HBEGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.",
author = "Kohei Miyata and Fusanori Yotsumoto and Satoshi Fukagawa and Chihiro Kiyoshima and {Sung Ouk}, Nam and Daichi Urushiyama and Tomohiro Ito and Takahiro Katsuda and Masamitsu Kurakazu and Ryota Araki and Ayako Sanui and Daisuke Miyahara and Masaharu Murata and Kyoko Shirota and Hiroshi Yagi and Tadao Takono and Kiyoko Kato and Nobuo Yaegashi and Kohei Akazawa and Masahide Kuroki and Shin'ichiro Yasunaga and Shingo Miyamoto",
year = "2017",
month = "7",
doi = "10.21873/anticanres.11779",
language = "English",
volume = "37",
pages = "3955--3960",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer

AU - Miyata, Kohei

AU - Yotsumoto, Fusanori

AU - Fukagawa, Satoshi

AU - Kiyoshima, Chihiro

AU - Sung Ouk, Nam

AU - Urushiyama, Daichi

AU - Ito, Tomohiro

AU - Katsuda, Takahiro

AU - Kurakazu, Masamitsu

AU - Araki, Ryota

AU - Sanui, Ayako

AU - Miyahara, Daisuke

AU - Murata, Masaharu

AU - Shirota, Kyoko

AU - Yagi, Hiroshi

AU - Takono, Tadao

AU - Kato, Kiyoko

AU - Yaegashi, Nobuo

AU - Akazawa, Kohei

AU - Kuroki, Masahide

AU - Yasunaga, Shin'ichiro

AU - Miyamoto, Shingo

PY - 2017/7

Y1 - 2017/7

N2 - Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HBEGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.

AB - Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HBEGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85021740161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021740161&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11779

DO - 10.21873/anticanres.11779

M3 - Article

C2 - 28668900

AN - SCOPUS:85021740161

VL - 37

SP - 3955

EP - 3960

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -